|
July 6, 2026
Dear Colleague,
The FDA works to safeguard the public against potential health risks, ensures the safety and efficacy of medical products, and the safety of our nation’s food supply and cosmetics. Your partnership, knowledge and engagement in the public health space are appreciated.
Sincerely,
The Public Engagement Staff
Public Engagement Staff | FDA
MedWatch: The FDA Safety Information and Adverse Event Reporting Program
The FDA’s medical product safety reporting program for health professionals, patients and consumers, MedWatch receives reports from the public and when appropriate, publishes safety alerts for FDA-regulated products. The most recent alerts/recalls are here:
Updates
 The U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) released its MUMS Blueprint for Success: 2026-2028 , a three-year strategic plan to modernize and expand the Minor Use and Minor Species (MUMS) program. The Blueprint outlines future FDA actions and proposals to improve the availability of safe and effective drugs for underserved animal populations – minor animal species, such as sheep, goats, fish, and exotic species, as well as major animal species like cattle, dogs, cats, and chickens, affected with uncommon diseases for which few or no drugs currently exist.
 The FDA has received an increasing number of reports of pets accidentally overdosing on Apoquel Chewable (oclacitinib chewable tablets), a flavored chewable medicine approved only for dogs. Accidental overdoses have been reported in both dogs and cats. However, cats are more likely than dogs to experience serious side effects if they take too much of the medication. As of April 2, 2026, there have been 259 reports of overdose in dogs and 64 reports in cats since the medication was approved by the FDA in June 2023.
View all Official FDA Guidance Documents and other Regulatory Guidance
You can search for documents using key words, and you can narrow or filter your results by product, date issued, FDA organizational unit, type of document, subject, draft or final status, and comment period.
Date: Tuesday, July 7, 2026; 9 a.m. - 1 p.m. ET
The FDA’s Center for Veterinary Medicine (CVM) will host the Third Annual Animal Drug User Fee Educational Conference. The conference provides educational sessions for stakeholders who are interested in the new animal drug approval process. The series of five annual educational conferences hosted by the FDA are described in the Animal Drug User Fee Act Reauthorization Performance Goals and Procedures Fiscal Years 2024 Through 2028.
Date: Thursday, July 9, 2026; noon - 1 p.m. ET
This lecture will present an analysis of Shigatoxigenic E. coli (STEC) prevalence in surface waters, sediment, soil, air and animal feces sampled across the Central Coastal agricultural growing region of California. Integrating findings from a multi-year environmental study, the presentation explores how STEC moves through and persists over time within a complex agricultural ecosystem.
View Upcoming FDA Meetings, Conferences and Workshops
Public meetings involving the FDA: Upcoming events, past meetings, meeting materials, and transcripts
About Us
The Public Engagement Staff resides within the Office of the Commissioner and falls under the Office of External Affairs. We aim to build stronger relationships with health professional organizations, patients and patient advocacy organizations, consumer groups, trade associations, think tanks and academia, and other interested parties, in order to better inform our policy making process, identify policy hurdles or misconceptions, and create strategic collaborations. For more information, please contact us at PublicEngagement@fda.hhs.gov. For patient specific inquiries, please contact us at Patients Ask FDA.
Did someone forward you this email? Sign up below!
|
